🏛️ Verified NIH Record • Updated 2026-07-07
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (NCT06602232)
A Pilot, Safety and Clinical Activity, Phase 1b Study of DR-01 in Adults With Alopecia Areata or Vitiligo
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Dren Bio
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Who can join: Review the eligibility criteria below.
Location: Dren Investigational Site — Northridge, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Dren Investigational Site — Northridge, California
- Dren Investigational Site — Miami, Florida
- Dren Investigational Site — Evans, Georgia
- Dren Investigational Site — Meridian, Idaho
- Dren Investigational Site — Indianapolis, Indiana
- Dren Investigational Site — West Lafayette, Indiana
- Dren Investigational Site — Worcester, Massachusetts
- Dren Investigational Site — Troy, Michigan
- Dren Investigational Site — Philadelphia, Pennsylvania
- Dren Investigational Site — Pittsburgh, Pennsylvania
- Dren Investigational Site — Chattanooga, Tennessee
- Dren Investigational Site — San Antonio, Texas
- Dren Investigational Site — Charlestown, New South Wales
- Dren Investigational Site — Darlinghurst, New South Wales
- Dren Investigational Site — Coorparoo, Queensland
- Dren Investigational Site — South Yarra, Victoria
- Dren Investigational Site — Fremantle, Washington
- Dren Investigational Site — Auckland,
- Dren Investigational Site — Christchurch,
- Dren Investigational Site — Grafton,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alopecia Areata
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Birmingham, Alabama
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) — Northridge, California
- Alopecia Areata Registry — San Francisco, California
- Intralesional Cyclosporine for Alopecia Areata — Sacramento, California
- A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) — Scottsdale, Arizona
Explore by condition: All Alopecia Areata clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.